These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19381019)

  • 21. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
    Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
    Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
    Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
    Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
    Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
    EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
    di Martino E; Alder O; Hurst CD; Knowles MA
    Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
    Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
    J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.
    Gorbenko O; Ovcharenko G; Klymenko T; Zhyvoloup O; Gaman N; Volkova D; Gout I; Filonenko V
    Hybridoma (Larchmt); 2009 Aug; 28(4):295-300. PubMed ID: 19663703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
    Blinova E; Samishina E; Deryabina O; Blinov D; Roshchin D; Shich E; Tumutolova O; Fedoseykin I; Epishkina A; Barakat H; Kaprin A; Zhandarov K; Perepechin D; Merinov D; Brykin G; Arutiunian K; Serebrianyi S; Mirontsev A; Kozdoba A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
    Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
    Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
    Trudel S; Ely S; Farooqi Y; Affer M; Robbiani DF; Chesi M; Bergsagel PL
    Blood; 2004 May; 103(9):3521-8. PubMed ID: 14715624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
    Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.
    Yin Y; Ren X; Smith C; Guo Q; Malabunga M; Guernah I; Zhang Y; Shen J; Sun H; Chehab N; Loizos N; Ludwig DL; Ornitz DM
    Dis Model Mech; 2016 May; 9(5):563-71. PubMed ID: 27056048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
    Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.
    Blick C; Ramachandran A; Wigfield S; McCormick R; Jubb A; Buffa FM; Turley H; Knowles MA; Cranston D; Catto J; Harris AL
    Br J Cancer; 2013 Jul; 109(1):50-9. PubMed ID: 23778527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
    Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
    Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation.
    Kong M; Wang CS; Donoghue DJ
    J Biol Chem; 2002 May; 277(18):15962-70. PubMed ID: 11827956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.
    Kotani N; Ishiura Y; Yamashita R; Ohnishi T; Honke K
    J Biol Chem; 2012 Oct; 287(44):37109-18. PubMed ID: 22932894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.